Skip to main content

OW32 documents

05/12/2025
OWMAG recommendation with starting and stopping criteria venetoclax and azacitidine for RR AML OW32 december 2025.pdf
05/12/2025
OWMAG decision rationale Ven+Aza RR AML OW32.pdf
05/12/2025
venetoclax plus azacitidine ESR non confidential for website OW32.pdf
05/12/2025
Equality and Health Impact Assessment venetoclax + azacitidine OW32.pdf
05/12/2025
Table 11 OW32.pdf
05/12/2025
Table 10 OW32.pdf
05/12/2025
Table 9 OW32.pdf
05/12/2025
Table 8 OW32.pdf
05/12/2025
Table 7 OW32.pdf
05/12/2025
Table 6 OW32.pdf
05/12/2025
Table 4 OW32.pdf
05/12/2025
Table 3 OW32.pdf
05/12/2025
Table 2 OW32.pdf
05/12/2025
Table 5 OW32.pdf
05/12/2025
Table 1 OW32.pdf
05/12/2025
Appendix 2 OW32.pdf
05/12/2025
Figure 2 OW32.pdf
05/12/2025
Figure 1 OW32.pdf
05/12/2025
Appendix 3 OW32.pdf
05/12/2025
Appendix 1 OW32.pdf
Follow AWTTC: